
Ivonescimab Prolonged PFS vs Pembrolizumab in PD-L1+, Treatment-Naïve NSCLC
Ivonescimab, an advanced PD-1/VEGF bispecific antibody, elicited prolonged progression-free survival (PFS) when compared with pembrolizumab (Keytruda) in patients with previously untreated PD-L1–positive advanced non–small cell lung cancer (NSCLC), …